Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study in Acute Pancreatitis

Next Previous
Trial Profile

Phase 3 study in Acute Pancreatitis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zegocractin (Primary)
  • Indications Pancreatitis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 24 Jun 2026 According to a CalciMedica media release, the company expects feedback from the FDA on the design of this trial in the third quarter of 2026.
  • 27 Mar 2025 According to a CalciMedica media release, the company plans to hold an end-of-Phase 2 meeting with the FDA around the middle of 2025 and expects to be in a position to initiate a Phase 3 program in AP and accompanying systemic inflammatory response syndrome (SIRS) around the end of 2025 pending additional funding.
  • 28 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top